Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders
View Patent ↗Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
1. A method for the treatment of a CD70-expressing cancer in a subject, the method comprising:
administering to the subject, in an amount effective for the treatment, an antibody-drug conjugate (ADC) comprising an antibody that binds to CD70 and a cytotoxic agent; wherein the cancer is multiple myeloma.
2. The method of claim 1 , wherein the antibody of the ADC competes for binding to CD70 with a monoclonal antibody comprising a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:50, and a light chain variable region having the amino acid sequence set forth in SEQ ID NO:51.
3. The method of claim 2 , wherein the antibody of the ADC comprises H1, H2, H3, L1, L2 and L3 complementarity-determining regions having, respectively, the amino acid sequences set forth in SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10; SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.
4. The method of claim 2 , wherein the antibody of the ADC is a humanized antibody.
5. The method of claim 1 , wherein the antibody of the ADC competes for binding to CD70 with a monoclonal antibody comprising a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:52, and a light chain variable region having the amino acid sequence set forth in SEQ ID NO:53.
6. The method of claim 1 , wherein the antibody is a chimeric antibody comprising a human constant region.
7. The method of claim 5 , wherein the antibody of the ADC comprises H1, H2, H3, L1, L2, and L3 complementarity-determining regions having the amino acid sequences set forth in SEQ ID NO:26, SEQ ID NO:28; SEQ ID NO:30; SEQ ID NO:36, SEQ ID NO:38 and SEQ ID NO:40, respectively.
8. The method of claim 1 , wherein the cytotoxic agent is selected from the group consisting of a DNA minor groove binding agent, a DNA minor groove alkylating agent, an enediyne, a duocarmycin, a maytansinoid, and a vinca alkaloid.
9. The method of claim 1 , wherein the cytotoxic agent is an anti-tubulin agent.
10. The method of claim 9 , wherein the cytotoxic agent is AFP or MMAE.
11. The method of claim 1 , wherein the antibody is conjugated to the cytotoxic agent via a linker.
12. The method of claim 11 , wherein the linker is cleavable under intracellular conditions.
13. The method of claim 12 , wherein the cleavable linker is a peptide linker cleavable by an intracellular protease.
14. The method of claim 13 , wherein the peptide linker comprises a dipeptide.
15. The method of claim 14 , wherein the dipeptide is a val-cit or a phe-lys dipeptide.
16. The method of claim 1 , wherein the subject is human.
17. The method of claim 1 , wherein the method comprises:
administering to the subject in need thereof from about one to about ten suboptimal dosages, over a period of about four to about ten days, of the antibody-drug conjugate.
18. The method of claim 15 , wherein the linker comprises the dipeptide val-cit, and the cytotoxic agent is MMAE, MMAF or AFP.
19. The method of claim 1 , wherein the antibody blocks binding of CD70 to CD27 receptor.
20. The method of claim 19 , wherein the cytotoxic agent is an anti-tubulin agent.
21. The method of claim 20 , wherein the anti-tubulin agent is AFP or MMAE.